Approximately 25% of Indian adults are overweight, driving increased use of GLP-1 receptor agonist drugs such as Wegovy, Rybelsus, Ozempic, and Mounjaro for weight loss. This trend reflects a shift toward medicalized obesity care in India, but it raises concerns about side effects, access disparities, and unregulated sales, including black-market activity. Patients using GLP-1 drugs have reported complications not commonly listed among known side effects, including new oral health issues dubbed "Ozempic teeth," characterized by dry mouth, nausea, and vomiting that can indirectly impact teeth and gums. Experts note that most users tolerate these medications without serious oral problems, but a subset experience notable side effects. Discussions are ongoing about expanding Medicare coverage for GLP-1 drugs to treat conditions beyond diabetes and weight loss. Strategies to mitigate side effects have been studied and shared in medical literature and patient experiences, highlighting the importance of careful dosing and monitoring.